donepezil hydrochloride (Aricept)

DRUG3 trials

Sponsors

Eisai Inc.

Conditions

Down SyndromeSevere Alzheimer's DiseaseVascular Dementia

Phase 2

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

TerminatedNCT00675025

Eisai Inc.Down Syndrome

Start: 2008-04-04End: 2008-12-15Updated: 2021-03-29

Phase 4

Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia

CompletedNCT00165763

Eisai Inc.Vascular Dementia

Start: 2005-09-30Updated: 2012-05-04

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

WithdrawnNCT00711204

Eisai Inc.Severe Alzheimer's Disease

Start: 2008-01-31Updated: 2012-12-10